These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 17823933

  • 1. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
    Zhang AL, Russell PJ, Knittel T, Milross C.
    Prostate; 2007 Nov 01; 67(15):1630-40. PubMed ID: 17823933
    [Abstract] [Full Text] [Related]

  • 2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.
    Cancer Gene Ther; 2000 Nov 01; 7(11):1469-80. PubMed ID: 11129289
    [Abstract] [Full Text] [Related]

  • 3. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H, Nguyen TH, Panasci L, Do P.
    Cancer; 2004 Dec 15; 101(12):2881-91. PubMed ID: 15529313
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 15; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 5. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
    Hara T, Omura-Minamisawa M, Kang Y, Cheng C, Inoue T.
    Int J Radiat Oncol Biol Phys; 2008 Aug 01; 71(5):1485-95. PubMed ID: 18640498
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Aug 01; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

  • 7. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
    Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine W, Mohiuddin M, Ahmed MM.
    Anticancer Res; 2002 Aug 01; 22(2A):825-30. PubMed ID: 12014658
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May 01; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
    Parker LP, Wolf JK, Price JE.
    Ann Clin Lab Sci; 2000 Oct 01; 30(4):395-405. PubMed ID: 11045764
    [Abstract] [Full Text] [Related]

  • 14. Enhanced radiosensitization of p53 mutant cells by oleamide.
    Lee YJ, Chung DY, Lee SJ, Ja Jhon G, Lee YS.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1466-74. PubMed ID: 16580498
    [Abstract] [Full Text] [Related]

  • 15. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
    Takei Y, Kadomatsu K, Goto T, Muramatsu T.
    Cancer; 2006 Aug 15; 107(4):864-73. PubMed ID: 16832814
    [Abstract] [Full Text] [Related]

  • 16. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer.
    Eiseman JL, Rogers FA, Guo Y, Kauffman J, Sentz DL, Klinger MF, Callery PS, Kyprianou N.
    Cancer Res; 1998 Nov 01; 58(21):4864-70. PubMed ID: 9809992
    [Abstract] [Full Text] [Related]

  • 17. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS.
    Prostate; 2003 Jun 01; 55(4):299-307. PubMed ID: 12712409
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
    King TC, Estalilla OC, Safran H.
    Semin Radiat Oncol; 1999 Apr 01; 9(2 Suppl 1):4-11. PubMed ID: 10210535
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.